Stock ACST ACASTI PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Acasti Pharma Inc.

Equities

ACST

CA00430K8656

Market Closed - Nasdaq
Other stock markets
 21:30:00 02/05/2024 BST 		5-day change 1st Jan Change
3.03 USD +6.31% Intraday chart for Acasti Pharma Inc. +3.47% +4.84%
02-12 Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
02-07 Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal
Acasti Pharma Inc. Announces Board Changes
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing
Acasti Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
Top Midday Decliners
Acasti Pharma to Implement 1-for-6 Reverse Stock Split
Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol
Acasti Pharma Says it has Aligned With FDA Protocol for Phase 3 Trial of GTX-104; Receives New Drug Application Guidance
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
Acasti Pharma Inc. Announces Scientific Advisory Board Appointments
Acasti Pharma Inc. Announces Executive Changes
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025
Acasti Pharma Inc. to Proceed with Phase 3 Clinical Safety Study for GTX-104
Acasti Pharma Inc. Announces CEO Changes
Acasti Pharma Inc. Announces Resignation of Jean-Marie Canan from Board of Directors and Member of Audit Committee and Governance and Human Resources Committee
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACST Stock
  4. News Acasti Pharma Inc.
  5. Other languages